MX376131B - Derivado del ester del acido heteroarilcarboxilico. - Google Patents

Derivado del ester del acido heteroarilcarboxilico.

Info

Publication number
MX376131B
MX376131B MX2014015287A MX2014015287A MX376131B MX 376131 B MX376131 B MX 376131B MX 2014015287 A MX2014015287 A MX 2014015287A MX 2014015287 A MX2014015287 A MX 2014015287A MX 376131 B MX376131 B MX 376131B
Authority
MX
Mexico
Prior art keywords
derivative
ester
heteroarylcarboxylic acid
heteroarylcarboxylic
acid
Prior art date
Application number
MX2014015287A
Other languages
English (en)
Other versions
MX2014015287A (es
Inventor
Taisuke Ichimaru
Takahiro Koshiba
Kayo Matsumoto
Tadakiyo Nakagawa
Koji Ohsumi
Tamotsu Suzuki
Munetaka Tokumasu
Tatsuhiro Yamada
Original Assignee
Ea Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co Ltd filed Critical Ea Pharma Co Ltd
Publication of MX2014015287A publication Critical patent/MX2014015287A/es
Publication of MX376131B publication Critical patent/MX376131B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos representados por la siguiente fórmula (I); (ver Fórmula) en donde cada símbolo es definido en la especificación, son útiles como inhibidores hiperglucémicos con una acción inhibitoria de la serina proteasa y como fármacos profilácticos o terapéuticos para la diabetes.
MX2014015287A 2012-06-14 2013-06-14 Derivado del ester del acido heteroarilcarboxilico. MX376131B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/517,805 US9024044B2 (en) 2012-06-14 2012-06-14 Heteroarylcarboxylic acid ester derivative
PCT/JP2013/067015 WO2013187533A1 (en) 2012-06-14 2013-06-14 Heteroarylcarboxylic acid ester derivative

Publications (2)

Publication Number Publication Date
MX2014015287A MX2014015287A (es) 2015-02-20
MX376131B true MX376131B (es) 2025-03-07

Family

ID=49756457

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015287A MX376131B (es) 2012-06-14 2013-06-14 Derivado del ester del acido heteroarilcarboxilico.

Country Status (8)

Country Link
US (3) US9024044B2 (es)
KR (1) KR102129716B1 (es)
AU (2) AU2013275197B2 (es)
BR (1) BR112014030966B1 (es)
CA (1) CA2876573C (es)
MX (1) MX376131B (es)
RU (1) RU2664544C2 (es)
WO (1) WO2013187533A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102822154B (zh) 2009-12-07 2016-06-01 味之素株式会社 杂芳基羧酸酯衍生物
WO2012169579A1 (ja) 2011-06-07 2012-12-13 味の素株式会社 ヘテロ環カルボン酸エステル誘導体
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
LT2975023T (lt) 2013-03-13 2018-08-10 Takeda Pharmaceutical Company Limited Guanidinbenzoinės rūgšties esterio junginys
RS62633B1 (sr) 2013-03-15 2021-12-31 Protagonist Therapeutics Inc Analozi hepcidina i njihove primene
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP3118197A4 (en) * 2014-03-11 2017-08-09 EA Pharma Co., Ltd. Production method for heteroarylcarboxylic acid ester derivative, production intermediate thereof, and crystal
EP3118196A4 (en) * 2014-03-11 2018-02-21 EA Pharma Co., Ltd. Method for producing heteroarylcarboxylic acid ester derivative, and production intermediate of same
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US9975903B2 (en) 2014-12-26 2018-05-22 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
SG11201705750WA (en) 2015-01-15 2017-08-30 Univ Osaka Method for inducing differentiation of corneal epithelial cells from pluripotent stem cells
JP6634070B2 (ja) 2015-03-27 2020-01-22 武田薬品工業株式会社 縮合複素環化合物
CN105175392B (zh) * 2015-08-28 2019-04-19 湖南大学 一类含噻吩结构羧酸化合物和含噻吩结构酰胺化合物及其制备方法
CN111542511A (zh) 2017-11-02 2020-08-14 宇部兴产株式会社 蛋白分解酶的双头型抑制剂
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP3820883A4 (en) 2018-07-12 2022-04-20 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021013742A1 (en) 2019-07-19 2021-01-28 Janssen Pharmaceutica Nv 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase
IL291783A (en) * 2019-10-02 2022-06-01 Domain Therapeutics ep4 prostaglandin e2 receptor antagonists
EP4090669A4 (en) 2020-01-15 2024-11-20 Janssen Biotech, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
SI4090670T1 (sl) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni zaviralci receptorja interlevkina-23 in njihova uporaba za zdravljenje vnetnih bolezni
WO2021166899A1 (ja) * 2020-02-17 2021-08-26 宇部興産株式会社 インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤
ES2982263T3 (es) * 2020-08-19 2024-10-15 Ea Pharma Co Ltd Agente terapéutico para enfermedad de hígado graso
IL316550A (en) 2020-11-20 2024-12-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
WO2022212698A1 (en) * 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Peptide inhibitors linked to fatty residues of the interleukin-23 receptor
TW202532060A (zh) * 2023-12-01 2025-08-16 日商Ｅａ製藥股份有限公司 醫藥組成物
WO2025115989A1 (ja) * 2023-12-01 2025-06-05 Ｅａファーマ株式会社 医薬組成物
WO2025211248A1 (ja) * 2024-04-04 2025-10-09 Ｅａファーマ株式会社 医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122075A (ja) 1984-07-10 1986-01-30 Torii Yakuhin Kk アミジン誘導体
US4563527A (en) 1984-07-19 1986-01-07 Torii & Co., Ltd. Amidine compounds
US5532267A (en) 1992-02-10 1996-07-02 Torii & Co., Ltd. Amidinonaphthyl furancarboxylate derivatives and acid addition salts therof
JPH05213927A (ja) 1992-02-10 1993-08-24 Torii Yakuhin Kk 新規フランカルボン酸アミジノナフチルエステル誘導体およびその酸付加塩
ATE178589T1 (de) 1994-09-20 1999-04-15 Ono Pharmaceutical Co Amidinophenol-derivate als protease-hemmende verbindungen
JPH08143529A (ja) 1994-09-20 1996-06-04 Ono Pharmaceut Co Ltd アミジノフェノール誘導体、その製造方法、およびアミジノフェノール誘導体を有効成分として含有するロイコトリエンｂ４拮抗剤、ホスホリパーゼａ２および／またはトリプシン阻害剤
AU2300699A (en) 1998-02-17 1999-08-30 Ono Pharmaceutical Co. Ltd. Amidino derivatives and drugs containing the same as the active ingredient
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US7671057B2 (en) 2004-11-08 2010-03-02 Ono Pharmaceutical Co., Ltd. Therapeutic agent for type II diabetes comprising protease-inhibiting compound
EP1843819A2 (en) 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
JP2008266174A (ja) 2007-04-18 2008-11-06 Kowa Co アミジノフェノール誘導体を有効成分とする糖化最終産物形成阻害剤
EP2225261B1 (en) 2007-12-03 2016-03-09 Obe Therapy Biotechnology Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
CN102822154B (zh) * 2009-12-07 2016-06-01 味之素株式会社 杂芳基羧酸酯衍生物
WO2012169579A1 (ja) 2011-06-07 2012-12-13 味の素株式会社 ヘテロ環カルボン酸エステル誘導体
PH12014500573A1 (en) 2011-09-15 2014-04-14 Astellas Pharma Inc Guanidinobenzoic acid compound
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative

Also Published As

Publication number Publication date
RU2664544C2 (ru) 2018-08-20
KR102129716B1 (ko) 2020-07-03
CA2876573A1 (en) 2013-12-19
US20160058734A1 (en) 2016-03-03
AU2013275197B2 (en) 2017-07-27
AU2013275197A1 (en) 2015-01-22
US9024044B2 (en) 2015-05-05
BR112014030966B1 (pt) 2022-07-05
KR20150023741A (ko) 2015-03-05
US20130338132A1 (en) 2013-12-19
MX2014015287A (es) 2015-02-20
AU2017251698A1 (en) 2017-11-09
RU2015100901A (ru) 2016-08-10
US20150099733A1 (en) 2015-04-09
US9227949B2 (en) 2016-01-05
WO2013187533A1 (en) 2013-12-19
CA2876573C (en) 2020-06-30
US9655879B2 (en) 2017-05-23
BR112014030966A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
MX376131B (es) Derivado del ester del acido heteroarilcarboxilico.
EA201391822A1 (ru) Новые производные пиридина
UA110471C2 (ru) 5-алкінілпіримідини
EA201591064A1 (ru) Новые производные пиридина
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
EA201390381A1 (ru) Триазиноксадиазолы
MX378194B (es) Compuestos organicos.
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201291317A1 (ru) Тетрагидропиридопиримидиновые производные
EA201591624A1 (ru) Новые производные пиразола
PH12015501933B1 (en) Novel pyridine derivatives
MY164790A (en) Purification of bio-based acrylic acid to crude and glacial acrylic acid
MX349548B (es) Compuestos de tienopirimidina.
IN2014MN01637A (es)
MX2014004920A (es) Nuevos derivados de pirazina.
MX360957B (es) Proceso de fabricación de adamantanamidas.
IN2015DN02668A (es)
MY191759A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
PH12013501665A1 (en) Cathepsin c inhibitors
CO7200259A2 (es) Nuevos derivados de piridina
NZ707087A (en) Novel flavonoid compounds and uses thereof
LT2012082A (lt) Nauji fotochrominiai junginiai, jų gamybos būdas ir tarpiniai junginiai jiems gauti
CY1116366T1 (el) Νεα μεθοδος για τη συνθεση αγομελατινης
UA64492U (en) 3-METHYL-7-β-HYDROXY-γ-(N-CHLOROPHENOXY)PROPYL-8-(2'-BROMO-3'-PHENYL)ALLYLIDENEHYDRAZINOXANTHINE EXHIBITING DIURETIC ACTION

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: EA PHARMA CO., LTD.

FG Grant or registration